Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tongjitang Receives Buy-Out Offer from CEO and Fosun

publication date: Apr 9, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tongjitang Chinese Medicines Company (同济堂药业) has received a buy-out offer from a JV comprised of Mr. Xiaochun Wang, who is the company’s Chairman and CEO, and Fosun Industrial, the Hong Kong conglomerate. The JV has offered $1.125 per share or $4.50 per ADS, a modest 19% premium to the ADS price. If Tongjitang’s shareholders accept the offer, the company would once again be a privately held entity. More details...

Stock Symbol: (NYSE: TCM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
CBPF2016
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors